Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/18/2865250/0/en/Ocular-Therapeutix-Announces-Positive-Topline-Phase-1-Data-for-AXPAXLI-in-Diabetic-Retinopathy.html
https://www.globenewswire.com/news-release/2024/04/16/2863461/0/en/Ocular-Therapeutix-Strengthens-Clinical-Team-with-Appointment-of-Key-Retinal-Leaders.html
https://www.globenewswire.com/news-release/2024/04/15/2862636/0/en/Ocular-Therapeutix-Executive-Chairman-Pravin-U-Dugel-MD-Becomes-President-and-CEO-Antony-Mattessich-is-Stepping-Down-as-President-and-CEO.html
https://www.globenewswire.com/news-release/2024/04/09/2859876/0/en/Ocular-Therapeutix-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4-to-Senior-Vice-President-of-Global-Head-of-Biometrics.html
https://www.globenewswire.com/news-release/2024/04/06/2858799/0/en/Ocular-Therapeutix-Announces-Positive-Phase-2-PAXTRAVA-Glaucoma-Data-at-the-American-Society-of-Cataract-and-Refractive-Surgery-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/26/2852253/0/en/Ocular-Therapeutix-To-Present-Data-at-the-2024-ASCRS-Annual-Meeting-American-Society-of-Cataract-and-Refractive-Surgery.html
https://www.globenewswire.com//news-release/2024/03/11/2844143/0/en/Ocular-Therapeutix-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html
https://www.globenewswire.com//news-release/2024/03/05/2840327/0/en/Ocular-Therapeutix-to-Release-Fourth-Quarter-and-Full-Year-2023-Results-on-March-11-2024.html
https://www.globenewswire.com//news-release/2024/02/22/2833588/0/en/Ocular-Therapeutix-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4-to-Newly-Appointed-Executive-Chairman-and-Chief-Strategy-Officer.html
https://www.globenewswire.com//news-release/2024/02/22/2833585/0/en/Ocular-Therapeutix-Inc-Announces-325-0-Million-Private-Placement.html